Cargando…

Upregulation of fatty acid synthase in MYC and BCL-2 double-expressor lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common and heterogeneous lymphoid malignancy. The subtype with MYC and BCL-2 double-expressor lymphoma (DEL) was defined by its aggressive nature and poor survival outcome. Therefore, the development of effective therapies for the DEL subtype is impe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Xing, Liu, Zhiliang, Luo, Qingfeng, Li, Jingao, Zhang, Weiwei, Shuang, Yuerong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882893/ https://www.ncbi.nlm.nih.gov/pubmed/33664809 http://dx.doi.org/10.3892/ol.2021.12506

Ejemplares similares

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

Double-Expressor Phenotype (BCL-2/c-MYC Co-expression) of Diffuse Large B-Cell Lymphoma and Its Clinicopathological Correlation
por: Hashmi, Atif A, et al.
Publicado: (2021)

Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma
por: Liu, Meng-Ke, et al.
Publicado: (2022)

Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors
por: Na, Hee Young, et al.
Publicado: (2019)

Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
por: Melchor, Javier, et al.
Publicado: (2023)

A Great Mimicker in Thoracic Spine: Spinal Double Expressor Lymphoma
por: Mufti, Muhammad, et al.
Publicado: (2018)

Case Report: Concurrent Occurrence of Abdominal Double Expressor Lymphoma and Jejunum Follicular Lymphoma
por: Takada, Ryutaro, et al.
Publicado: (2021)

Double-Expressor Appendiceal Burkitt's Lymphoma: A Case Report and Literature Review
por: Dukmak, Osama N., et al.
Publicado: (2022)

Multiple osteolytic lesions due to Double-Expressor Primary non-Hodgkin Lymphoma of the Bone
por: Papageorgiou, Sotirios, et al.
Publicado: (2020)

Double or triple-expressor lymphomas: prognostic impact of immunohistochemistry in patients with diffuse large B-cell lymphoma
por: Peña, Camila, et al.
Publicado: (2020)

Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility
por: Craig, Jeffrey W., et al.
Publicado: (2018)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

PB2122: THE EFFICACY OF THE STANDARD AND INTENSIVE CHEMOTHERAPY IN ELDERLY PATIENTS WITH DOUBLE- AND TRIPLE-EXPRESSOR LYMPHOMA.
por: Fujita, M., et al.
Publicado: (2022)

Treatment Outcomes and Clinical Relevance in Patients with Double Expressor DLBCL
por: Rungwittayatiwat, Sirapat, et al.
Publicado: (2021)

Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma
por: Liu, Xiaoqian, et al.
Publicado: (2022)

Double-hit and double-expressor primary central nervous system lymphoma: Experience from North India of an infrequent but aggressive variant
por: Parkhi, Mayur, et al.
Publicado: (2023)

Triple Expressor Lymphoma: Presentation With Acute Paraparesis Due to Spinal Cord Compression
por: Alburqueque-Melgarejo, Joseph, et al.
Publicado: (2022)

MYC/BCL2 double- and MYC/BCL2/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21)
por: Takeoka, Kayo, et al.
Publicado: (2022)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019)

Primary Cutaneous Diffuse Large B-Cell Lymphoma of the Upper Limb: Double Hit/Double Expressor with CNS Involvement: From Hospice to Remission
por: Castillo, Brenda S., et al.
Publicado: (2019)

DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis
por: Zhan, Jing, et al.
Publicado: (2022)

Prognostic evaluation of system immune-inflammatory index and prognostic nutritional index in double expressor diffuse large B-cell lymphoma
por: Su, Fang, et al.
Publicado: (2023)

BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma
por: Esteve-Arenys, Anna, et al.
Publicado: (2018)

Double-hit lymphoma (rearrangements of MYC, BCL-2) during pregnancy: A case report
por: Xie, Fan, et al.
Publicado: (2021)

Double‑hit primary lymphoma (MYC and BCL2) in the bilateral ovary: A case report
por: Zhang, Yan, et al.
Publicado: (2023)

MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
por: Wang, Yanjie, et al.
Publicado: (2023)

High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival
por: Yi, Shuhua, et al.
Publicado: (2015)

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
por: Dodero, Anna, et al.
Publicado: (2021)

Educational Case: Gastric High-Grade B-Cell Lymphoma With MYC and BCL2 Gene Rearrangement (Double-Hit Lymphoma)
por: Betts, Elham Vali, et al.
Publicado: (2020)

Primary, non-germinal center, double-expressor diffuse large B cell lymphoma confined to a uterine leiomyoma: A case report
por: Martin, Alexandra, et al.
Publicado: (2017)

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
por: Dodero, A., et al.
Publicado: (2019)

Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis
por: Jia, Jiaoyuan, et al.
Publicado: (2020)

Case report: Successful management of a refractory double-expressor diffuse large B-cell lymphoma patient under the guidance of in vitro high-throughput drug sensitivity test
por: Xing, Lijie, et al.
Publicado: (2023)

Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma
por: Li, Shaoying, et al.
Publicado: (2016)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment
por: Singh, Aditi, et al.
Publicado: (2022)

A Conservative Approach to the Treatment of a Rare Case of Cervical Spine Double Expressor Diffuse Large B-cell Lymphoma: A Case Report
por: Chen, Wesley, et al.
Publicado: (2022)

Prevalence and characteristics of non-lactate and lactate expressors in septic shock
por: Mackenhauer, Julie, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_otapmq8qtfbunmimg6o01cf288